Subsequent Events - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands |
1 Months Ended | 9 Months Ended | |||
|---|---|---|---|---|---|
Oct. 28, 2024 |
Nov. 18, 2015 |
Nov. 04, 2024 |
Sep. 30, 2024 |
Sep. 30, 2023 |
|
| Subsequent Event [Line Items] | |||||
| Proceeds from issuance of ordinary shares, net of transaction costs | $ 12,814 | $ 445 | |||
| Pfizer License Agreement | |||||
| Subsequent Event [Line Items] | |||||
| Regulatory milestone payments upon approval of product | $ 20,000 | ||||
| Regulatory and sales milestone deferred payment annual rate | 8.00% | ||||
| Subsequent Events | Pfizer License Agreement | |||||
| Subsequent Event [Line Items] | |||||
| Regulatory milestone deferred/intends to defer payment period | 2 years | ||||
| Subsequent Events | Sales Agreement With H.C. Wainwright | |||||
| Subsequent Event [Line Items] | |||||
| Number of ordinary shares sold | 4,500,000 | ||||
| Offering price per share | $ 1.55 | ||||
| Proceeds from issuance of ordinary shares, net of transaction costs | $ 6,700 | ||||
| X | ||||||||||
- Definition Regulatory and sales milestone deferred payment annual rate. No definition available.
|
| X | ||||||||||
- Definition Regulatory milestone deferred/intends to defer payment period. No definition available.
|
| X | ||||||||||
- Definition Regulatory milestone payments upon approval of product. No definition available.
|
| X | ||||||||||
- Definition The cash inflow from the additional capital contribution to the entity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The number of shares issued or sold by the subsidiary or equity method investee per stock transaction. No definition available.
|
| X | ||||||||||
- Definition Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. No definition available.
|
| X | ||||||||||
- Definition Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|